Pulmonx Corp
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
LUNG$2.800.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Years Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenue | $83,789 | $68,675 |
| Cost of goods sold | 21,788 | 17,923 |
| Gross profit | 62,001 | 50,752 |
| Operating expenses | ||
| Research and development | 17,570 | 18,080 |
| Selling, general and administrative | 102,135 | 94,607 |
| Total operating expenses | 119,705 | 112,687 |
| Loss from operations | (57,704) | (61,935) |
| Interest income | 5,061 | 5,568 |
| Interest expense | (3,507) | (3,232) |
| Other income (expense), net | 256 | (673) |
| Net loss before tax | (55,894) | (60,272) |
| Income tax expense | 500 | 571 |
| Net loss | (56,394) | (60,843) |
| Other comprehensive (loss) income | ||
| Currency translation adjustment | (466) | 671 |
| Change in unrealized (losses) gains on marketable securities | (61) | 394 |
| Total other comprehensive (loss) income | (527) | 1,065 |
| Comprehensive loss | $(56,921) | $(59,778) |
| Net loss per share attributable to common stockholders, basic and diluted | $(1.44) | $(1.60) |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 39,111,073 | 37,974,567 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.